ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
Adherence to stage-specific treatment guidelines for patients with colon cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Exploring disparities in adherence to colorectal cancer clinical practice guidelines and associated survival outcomes: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literature.Implementation science : IS · 2020Pooled it
- Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review.The oncologist · 2013Pooled it
- Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management.European journal of nuclear medicine and molecular imaging · 2022Trial
- Radiomic analysis for predicting prognosis of colorectal cancer from preoperativeJournal of translational medicine · 2022Trial
- Real-World Achievement of Guideline-Concordant Treatment and Survival in Osteosarcoma: A Nationwide Registry Study.Cancer science · 2026Article
- Black-White disparities across the colorectal cancer care continuum in the USA.Nature reviews. Gastroenterology & hepatology · 2025Review
- Less Is More: Risk Factors and Survival Outcomes of Overtreatment for Early-Stage Colorectal Cancer.Journal of surgical oncology · 2025Article
- NCCN guideline concordance in colon and rectal cancer patients within a comprehensive health system.American journal of surgery · 2025Article
- Novel immune-nutritional prognostic ratio predicts long-term survival in stage I-III colorectal cancer.Frontiers in oncology · 2025Article
- Article
- Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?Current treatment options in oncology · 2024Review
- Association Between Racial and Socioeconomic Disparities and Hospital Performance in Treatment and Outcomes for Patients with Colon Cancer.Annals of surgical oncology · 2024Article
- Combination of DNA ploidy, stroma, and nucleotyping predicting prognosis and tailoring adjuvant chemotherapy duration in stage III colon cancer.Therapeutic advances in medical oncology · 2024Article
- Variations in the Type of Adjuvant Chemotherapy Among Stage III Colon Cancer Patients in England.Journal of gastrointestinal cancer · 2023Article
- Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.Clinical and experimental nephrology · 2023Article
- Association of Rural Residence and Receipt of Guideline-Concordant Care for Locoregional Colon Cancer.Annals of surgical oncology · 2023Article
- Clinician attitudes towards cancer treatment guidelines in Australia.BMC research notes · 2023Article
- The effects of chemotherapy, primary tumor location and histological subtype on the survival of stage III colon cancer patients.BMC gastroenterology · 2023Article
- Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer.Journal of cancer research and clinical oncology · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeAdherence to evidence-based treatment guidelines has been proposed as a measure of cancer care quality. We sought to determine rates of and factors associated with adherence to the National Comprehensive Cancer Network (NCCN) treatment guidelines for colon cancer. PATIENTS AND
methodsPatients within the National Cancer Data Base treated for colon adenocarcinoma (2003 to 2007) were identified. Adherence to stage-specific NCCN guidelines was determined based on disease stage. Hierarchical regression analyses were performed to identify factors predictive of adherence, overtreatment, and undertreatment.
resultsA total of 173,243 patients were included in the final cohort, 123,953 (71%) of whom were treated according to NCCN guidelines. Patients with stage I disease were more likely to receive guideline-based treatment (96%) than patients with stage II (low risk, 66%; high risk, 36%), III (71%), or IV (73%) disease (P < .001). Adherence to consensus-based guidelines increased over time. Factors associated with adherence across all stages included age, Charlson-Deyo comorbidity index score, later year of diagnosis, and insurance status. Among patients with high-risk stage II or stage III disease, older patients with pre-existing comorbidities and patients with lower socioeconomic status were less likely to be offered adjuvant chemotherapy. Among patients with stage I and II disease, young, healthy patients were more likely to be recommended chemotherapy, in discordance with NCCN guidelines.
conclusionSignificant variation exists in the treatment of colon cancer, particularly in treatment of high-risk stage II and stage III disease. The impact of nonadherence to guidelines on patient outcomes needs to be further elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.